Helixgate

Helixgate

Uncategorized

Using versus selling lucrative PRVs: Moderna’s cautionary tale

Using versus selling lucrative PRVs: Moderna’s cautionary tale

Published

on

As the prices paid for priority review vouchers (PRVs) have crept up over the past year — the last two have sold for at least $200 million each — companies now have to make difficult decisions on …​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

FDA approves once-daily HIV pill from Merck

Published

on

A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading drugmakers in a field many biotechs have deserted.

The FDA greenlit …

Continue Reading

Uncategorized

Flu vaccine no longer mandated for U.S. troops, defense secretary says

WASHINGTON — Defense Secretary Pete Hegseth announced Tuesday that the U.S. military will no longer require all American troops to get the flu vaccine, citing “medical autonomy” and religious freedom.

“The notion that a flu vaccine must be mandatory for every service member, everywhere, in every circumstance at all times is just overly broad and not rational,” Hegseth said in a video posted on social media.

Read the rest…

Read More

Published

on

WASHINGTON — Defense Secretary Pete Hegseth announced Tuesday that the U.S. military will no longer require all American troops to get the flu vaccine, citing “medical autonomy” and religious freedom.

“The notion that a flu vaccine must be mandatory for every service member, everywhere, in every circumstance at all times is just overly broad and not rational,” Hegseth said in a video posted on social media.

Read the rest…

Read More

Continue Reading

Uncategorized

‘It’s just the beginning’ for pancreatic cancer’s long-awaited breakthrough

Published

on

SAN DIEGO — Since Herceptin’s approval in 1998, breast cancer has been reshaped from a near-term death sentence into — in many cases — a chronic disease. Now, researchers hope daraxonrasib from Revolution Medicines will launch the same …

Continue Reading
Advertisement

Trending